Thermo Fisher Scientific has forecast COVID-19 testing revenues will come in 100% above the expectations of Evercore ISI analysts in 2022 as testing demand returns amid the delta variant surge.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,